Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13459861 | 0.80 | CCR1 (0.34) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL20020427 | 0.77 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL15479688 | 0.77 | — | — | |
| SCHEMBL30774215 | 0.73 | HTT (0.36) | — | |
| SCHEMBL17675123 | 0.70 | NNMT (0.49) | — | |
| SCHEMBL23394674 | 0.69 | — | — | |
| SCHEMBL19157444 | 0.69 | CCR1 (0.32) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL9538730 | 0.68 | — | — | |
| SCHEMBL29909946 | 0.68 | — | — | |
| SCHEMBL15760112 | 0.68 | GSK3A (0.36) | CCR1CCR5CCR8NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020227484-A1 | SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-12 | — | — | WO | disclosed |
| EP-3287459-B1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | GUIZHOU BAILING GROUP PHARMACEUTICAL CO LTD (CN) | 2020-09-02 | — | — | EP | disclosed |
| US-10183949-B2 | Pyrimidinone derivative having autotaxin-inhibitory activity | THE UNIVERSITY OF TOKYO (JP) | 2019-01-22 | — | — | US | disclosed |
| EP-2935248-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2703392-B1 | 5-MEMBERED RING AROMATIC HETEROCYCLIC DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2017-06-14 | — | — | EP | disclosed |
| EP-0395244-B1 | Pyridine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1997-02-19 | — | — | EP | disclosed |
| US-5194439-A | 5-HT Agonists or Antagonists, Nervous System Disorders, Hypotensive Agents | JOHN WYETH & BROTHER LIMITED (GB) | 1993-03-16 | — | — | US | disclosed |
| US-5075303-A | Central nervous system disorders | JOHN WYETH & BROTHER LIMITED (GB) | 1991-12-24 | — | — | US | disclosed |
| EP-0395244-A1 | Pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183949-B2 | Pyrimidinone derivative having autotaxin-inhibitory activity | ENPP2, ITPA, IMPA1 | CCR1 3502/4885CCR5 3305/4885CCR8 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.